

****Published January 2024****

MarketVIEW: *Neisseria gonorrhoeae* vaccines (CAT: VAMV091)

Product Name	:	MarketVIEW: <i>Neisseria gonorrhoeae</i> vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (>235 slides.pdf) + forecast model(s) (.xls)
Therapeutic Area	:	New bacterial vaccines
Publication date	:	January 2024
Catalogue No	:	VAMV091

Background

Neisseria gonorrhoeae (Ng) is Gram-negative bacterium that caused ~82m new infections in 2020 (15-49 yrs) and is responsible for the 2nd most common sexually transmitted infection (STI), **gonorrhoea**. Although mostly asymptomatic, in the female, ascending Ng infections can result in severe sexual reproductive health (SRH) outcomes of **pelvic inflammatory disease (PID)**, **ectopic pregnancy**, and **infertility**. Ng infection can also elevate the risk for **HIV acquisition**/transmission and cause neonatal conjunctivitis which can cause **blindness**. Although Ng infections are generally treatable with antibiotics, the bacterium has a remarkable ability to acquire **antimicrobial resistance** against successive classes of antibiotics. This is considered a critical threat by the **World Health Organisation (WHO)**.

A prophylactic ***Neisseria gonorrhoeae*-specific vaccine** impacting upon gonococcal infection could reduce adverse SRH outcomes and alleviate gonococcal AMR. It could be targeted routinely to adolescents/young adults or high-risk groups (GBMSM) associated with the highest number of diagnoses. Notable vaccines in development are **GSK4348413** (Phase 1/2), the **Gonovac** project (Jenner Institute), **Avacc-11** (Intravacc), **EVX-B2** (Evaxion) and, **Limatech Bio AG** (hexavalent approach). *Meningococcal* serogroup B vaccines notably GSK's **Bexsero®** and newer pentavalent approaches will have global utility due to **OMV** and **NHBP** components.

This **MarketVIEW** product is a comprehensive Executive Presentation (>225 slides, .pdf) and interactive MS-Excel forecast model (120 worksheets, .xls) which investigate the scenario-based uptake and commercial potential of *Neisseria gonorrhoeae* **specific** and **menB** vaccines across key target groups in 10 high-income nations (public/private) worldwide. A thorough review of the latest disease background/epidemiology/resistance trends data is presented along with discussion of latest understanding of vaccinology/R&D competitor landscape. The analysis contains an in-depth **commercial assessment** of potential *Neisseria gonorrhoeae* specific vaccine profiles with discussion around target population rationale, potential uptake, pricing, and clinical development feasibility/issues. A commercial investigation into the cross-protective capacity of monovalent and pentavalent *meningococcal* **serogroup B** vaccines is also included re: recent UK JCVI November 2023 policy.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to *Neisseria gonorrhoeae* epidemiology and resistance trends in each respective market/globally. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of bacterial pathogens has also been utilised.

PRODUCT CONTENTS:

Published January 2024 (CAT No: VAMV091)

****This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

Contents – Summary presentation (.pdf)



Contents

Author's notes

Executive summary

[SECTION 1] *Neisseria gonorrhoeae* vaccines: commercial model – key outputs

[SECTION 2] *Neisseria gonorrhoeae*: the pathogen, disease background, virulence & pathogenesis

[SECTION 3] *Neisseria gonorrhoeae*: diagnosis, treatment & management, screening & prevention

[SECTION 4] *Neisseria gonorrhoeae*: review of antimicrobial resistance data/key trends

[SECTION 5] *Neisseria gonorrhoeae*: review of global epidemiology & impact, economic burden

[SECTION 6] *Neisseria gonorrhoeae*: history, vaccine development, current R&D

[SECTION 7] *Neisseria gonorrhoeae*: potential impact of vaccination [menB & specific vaccines]

[SECTION 8] Meningococcal vaccines, **Bexsero**®, **Trumemba**®, **Penbraya**[™] – commercial analysis

[SECTION 9] *Neisseria gonorrhoeae* vaccines: rationale and need for vaccine, preferred product characteristics

[SECTION 10] *Neisseria gonorrhoeae* vaccines: modelling commercial potential [menB & specific vaccines]

References/bibliography

About **VacZine Analytics**

Disclaimer

SNAPSHOT

PAGES: >225 slides fully referenced/sourced. Available in .pdf form

Contents – MS-Excel workbook (.xls)



4 uptake scenarios LO and HI for menB and gonococcal specific vaccines across relevant target segments

9 countries (5 groups) included in global demand model to 2035

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$13,995.00**/ GBP **£11,200.00**[#] (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – available upon request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd
Warren (Carlton) House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and "the spiral logo" are UK Registered Trademarks, 2009



Since 2007

